Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2021-01-26 Earnings Release
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
2020年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2020 annual performance forecast (业绩预告) for Jinling Pharmaceutical Co., Ltd. It covers the period from January 1, 2020 to December 31, 2020, providing estimated net profit and earnings per share figures, along with explanations for performance changes. It explicitly states that the forecast is unaudited and that the final audited financial data will be disclosed in the formal 2020 annual report. The document is short (1881 characters) and serves as a preliminary earnings forecast rather than a full financial report. It does not contain actual audited financial statements or comprehensive financial analysis. Therefore, it fits the definition of an Earnings Release (ER), which is an initial announcement of periodic financial results with key highlights only. FY 2020
2021-01-26 Chinese
关于召开2021年第一次临时股东大会的提示性公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed announcement about the convening of the 2021 first extraordinary general meeting (临时股东大会) of Jinling Pharmaceutical Co., Ltd. It includes information about the meeting date, voting procedures, agenda items, and proxy forms. It does not contain financial statements or results but rather logistical and procedural details for shareholders to participate in the meeting. The document is under 5,000 characters and serves as a notice or announcement for the meeting rather than the meeting materials or results themselves. Therefore, it fits best into the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is a notice about the meeting and voting procedures rather than solicitation materials or voting results, the most appropriate classification is Proxy Solicitation & Information Statement (PSI).
2021-01-22 Chinese
第八届董事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the sixth meeting of the eighth board of directors of Jinling Pharmaceutical Co., Ltd. It includes details about the meeting date, voting results, and references to related announcements and documents published elsewhere. The content focuses on board decisions and procedural matters rather than full financial data or detailed reports. The document length is short (1260 characters), and it serves as a public notice of board meeting outcomes rather than a full report or presentation. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2021-01-11 Chinese
公司章程修订对照表
Governance Information Classification · 95% confidence The document is a detailed comparison table showing amendments to the articles of association (章程修订对照表) of Jinling Pharmaceutical Co., Ltd. It focuses on governance structure changes, particularly related to the company's party committee and board responsibilities. There is no financial data, earnings information, or regulatory filing references. The content is about governance rules and internal company structure, which aligns with Governance Information (CGR). The document length is over 5,000 characters and contains substantive content, not just an announcement or notice.
2021-01-11 Chinese
第八届监事会第四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolution from the fourth meeting of the eighth Supervisory Board of Jinling Pharmaceutical Co., Ltd. It includes details about the meeting notice, attendance, voting results, and compliance with laws and company articles. There is no financial data, no mention of annual or interim reports, no audit information, or other report types. The document is a regulatory announcement about a board meeting resolution, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories like Board/Management Information (MANG) which is for changes in board or management, nor is it a report or presentation. The document length is short and it is an announcement of a meeting resolution, not a report itself.
2021-01-11 Chinese
独立董事关于公司第八届董事会第六次会议审议的有关议案及相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on the company's board meeting resolutions, specifically regarding the 2021 annual related party transactions. It references compliance with company law, securities law, stock exchange listing rules, and internal governance documents. The content is focused on governance and board-level approval of related party transactions, not on financial results, audit, or earnings. The document is a formal opinion from independent directors on board matters, which fits best under Board/Management Information (MANG) as it relates to board meeting decisions and governance opinions rather than a full report or announcement of voting results.
2021-01-11 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.